European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (eortc) [and] European Association for Cancer Research (eacr)
Overview
The European Journal of Cancer is the official journal for the European Organization for Research and Treatment of Cancer (EORTC) and the European Association for Cancer Research (EACR). It publishes high-quality research articles, reviews, and commentaries on all aspects of cancer research and treatment, with a focus on advancing knowledge and improving patient outcomes in Europe and beyond.
Details
Details
Abbr.
Eur J Cancer
Start
1990
End
Continuing
Frequency
Eighteen no. a year, 2000-
p-ISSN
0959-8049
e-ISSN
1879-0852
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 392
245
SJR / Ranks: 825
2501
CiteScore / Ranks: 1136
11.10
JIF / Ranks: 623
8.4
Recent Articles
1.
Desai A, Bagchi A, Armstrong A, van Tilburg C, Basu E, Robinson G, et al.
Eur J Cancer
. 2025 Mar;
220:115308.
PMID: 40086048
Background: Entrectinib, a central nervous system (CNS)-penetrant TRK/ROS1 inhibitor, has demonstrated clinical activity in children with NTRK1/2/3 or ROS1 fusion-positive extracranial solid and CNS tumours. We present integrated data of...
2.
Zarfati M, Soffer S, Nadkarni G, Klang E
Eur J Cancer
. 2025 Mar;
220:115341.
PMID: 40068371
Retrieval-Augmented Generation (RAG) pairs large language models (LLMs) with recent data to produce more accurate, context-aware outputs. By converting text into numeric embeddings, RAG locates and retrieves relevant "chunks" of...
3.
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, et al.
Eur J Cancer
. 2025 Mar;
220:115338.
PMID: 40068370
Background: Larotrectinib is the first-in-class, highly selective TRK inhibitor with demonstrated efficacy in various TRK fusion solid tumours. We report the efficacy and safety of larotrectinib in patients with TRK...
4.
Rieke D, Bitzer M, Bleckmann A, Desuki A, Ernst T, Esposito I, et al.
Eur J Cancer
. 2025 Mar;
220:115331.
PMID: 40058270
Precision oncology is a multi-step process including patient selection, tumor profiling, molecular tumor board discussion and personalized cancer management. So far, it remains largely unstandardized. The implementation of precision oncology...
5.
Capasso I, Perrone E, Duranti S, Giannarelli D, Nero C, Cordisco E, et al.
Eur J Cancer
. 2025 Mar;
220:115344.
PMID: 40058269
Background: One third of endometrial carcinomas (ECs) presents with mismatch repair deficiency (MMRd). Of these, 70 % are caused by somatic hypermethylation of MLH1 promoter; the remaining cases are determined...
6.
Dodkins J, Cook A, Mayne E, Parry M, Parry M, Boyle J, et al.
Eur J Cancer
. 2025 Mar;
220:115335.
PMID: 40056561
Background And Objective: International guidelines recommend treatment intensification combining docetaxel or androgen receptor pathway inhibitors with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer (mHSPC). However, evidence suggests underuse in...
7.
Jansen P, Galetzka W, Thielmann C, Murali R, Zaremba A, Standl F, et al.
Eur J Cancer
. 2025 Mar;
220:115337.
PMID: 40056560
Background: TERT promoter mutations are the most prevalent mutations in melanoma. In this study, we investigated clinical characteristics and survival after first line therapies in a cohort of melanoma patients...
8.
Vener C, Lillini R, De Angelis R, Bonfarnuzzo S, Poirel H, Trama A, et al.
Eur J Cancer
. 2025 Mar;
220:115231.
PMID: 40056559
Background: EUROCARE, a European population-based cancer project, has shown geographical survival disparities for myeloid neoplasms (MN) suggesting healthcare inequalities. Total National Health Expenditure (TNHE) might influence population-based MN survival. We...
9.
Karimova A, Khalitova A, Suezov R, Markov N, Mukhamedshina Y, Rizvanov A, et al.
Eur J Cancer
. 2025 Mar;
220:115332.
PMID: 40048925
Tumor-associated macrophages (TAMs) play a pivotal role in the tumor microenvironment (TME), actively contributing to the formation of an immunosuppressive niche that fosters tumor progression. Consequently, there has been a...
10.
Lehmann J, Dragan T, Rammant E, de Ligt K, Lai-Kwon J, Lidington E, et al.
Eur J Cancer
. 2025 Mar;
220:115333.
PMID: 40043551
Background: Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used in practice. Methods: We...